Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan;78(1):1-8.
doi: 10.1002/jmv.20499.

Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals

Linqi Zhang  1 , Fengwen Zhang, Wenjie Yu, Tian He, Jian Yu, Christopher E Yi, Lei Ba, Wenhui Li, Michael Farzan, Zhiwei Chen, Kwok-Yung Yuen, David Ho
Affiliations

Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals

Linqi Zhang et al. J Med Virol. 2006 Jan.

Abstract

Most of the SARS-CoV-infected patients spontaneously recovered without clinical intervention while a small percentage succumbed to the disease. Here, we characterized temporal changes in N protein-specific and S glycoprotein-specific neutralizing antibody (Nab) responses in infected patients who have either recovered from or succumbed to SARS-CoV infection. Recovered patients were found to have higher and sustainable levels of both N protein-specific and S glycoprotein-specific Nab responses, suggesting that antibody responses likely play an important role in determining the ultimate disease outcome of SARS-CoV-infected patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW, Poutanen SM, Detsky AS. 2003. Clinical Features and Short‐term Outcomes of 144 Patients With SARS in the Greater Toronto Area. Jama 289: 2801–2809. - PubMed
    1. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY. 2004. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 59: 252–256. - PMC - PubMed
    1. Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, Abu‐Raddad LJ, Ho LM, Thach TQ, Chau P, Chan KP, Lam TH, Tse LY, Tsang T, Liu SH, Kong JH, Lau EM, Ferguson NM, Anderson RM. 2003. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361: 1761–1766. - PMC - PubMed
    1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967–1976. - PubMed
    1. Giroglou T, Cinatl J, Jr. , Rabenau H, Drosten C, Schwalbe H, Doerr HW, von Laer D. 2004. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol 78: 9007–9015. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

  NODES
twitter 2